Y-Intercept (HK)
NBIX icon

Y-Intercept (HK)’s Neurocrine Biosciences NBIX Stock Holding History

Y-Intercept (HK)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.5M Buy
+73,778
New +$11.9M 0.23% 76
2026
Q1 		– Sell
-44,837
Closed -$6.36M – 1888
2025
Q4 		$6.36M Buy
44,837
+33,654
+301% +$4.88M 0.14% 155
2025
Q3 		$1.57M Buy
+11,183
New +$1.52M 0.04% 749
2025
Q2 		– Sell
-13,202
Closed -$1.46M – 1886
2025
Q1 		$1.46M Buy
+13,202
New +$1.67M 0.1% 268
2024
Q4 		– Sell
-31,781
Closed -$3.66M – 1498
2024
Q3 		$3.66M Buy
+31,781
New +$4.36M 0.22% 82
2024
Q2 		– Sell
-3,891
Closed -$537K – 1735
2024
Q1 		$537K Buy
+3,891
New +$531K 0.04% 676
2023
Q3 		– Sell
-3,937
Closed -$371K – 1409
2023
Q2 		$371K Sell
3,937
-2,279
-37% -$223K 0.04% 691
2023
Q1 		$629K Buy
6,216
+96
+2% +$10K 0.07% 416
2022
Q4 		$731K Buy
6,120
+2,475
+68% +$290K 0.11% 299
2022
Q3 		$387K Buy
+3,645
New +$370K 0.04% 626
2021
Q4 		– Sell
-2,738
Closed -$263K – 779
2021
Q3 		$263K Buy
+2,738
New +$259K 0.05% 505

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Y-Intercept (HK)'s NBIX Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 73,778 shares worth $10.5M. The stake represents 0.23% of the portfolio and ranks #76 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in NBIX as recently as Q4 2025.

Y-Intercept (HK) first reported a position in NBIX in Q3 2021 and has held it in 11 quarters since. 365 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Y-Intercept (HK) held 73,778 shares of Neurocrine Biosciences worth $10.5M as of Q3 2026.
  • Neurocrine Biosciences was a new Y-Intercept (HK) position in Q3 2026.
  • Neurocrine Biosciences made up 0.23% of Y-Intercept (HK)'s portfolio in Q3 2026, its #76 holding.
  • Y-Intercept (HK) first reported a position in Neurocrine Biosciences in Q3 2021 and has held it in 11 quarters since.
  • 365 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.